The FDA is committing to creating clear regulatory rules for medical devices powered by generative artificial intelligence, addressing a growing gap between rapid AI innovation and government oversight. Rick Abramson, director of the FDA's Digital Health Center of Excellence, told STAT that the agency will release formal policy guidance documents spelling out how it plans to regulate these emerging technologies.

Why Does the FDA Need New AI Rules for Medical Devices?

Generative AI, the type of artificial intelligence behind tools like ChatGPT, is increasingly being integrated into medical devices and healthcare software. These systems can analyze patient data, assist with diagnoses, and help doctors make treatment decisions. However, the regulatory framework governing traditional medical devices wasn't designed for AI systems that learn and adapt over time, creating uncertainty for companies developing these tools and confusion for healthcare providers trying to understand whether they're safe and effective.

The FDA has been working to catch up with the technology, but companies and healthcare organizations have been waiting for clear guidance on what the agency expects. "The ecosystem is expecting clarity," Abramson explained. "We seek to provide that clarity, and I'll also throw in that I think the ecosystem can expect not only broad guidance on the overall topic of generative AI, but also some more narrowly constructed specialty guidance on particular generative AI topics of special interest or special complexity".

What Will the FDA's New Guidance Cover?

According to Abramson, the FDA's approach will include multiple layers of regulation tailored to different types of AI applications in healthcare. The agency is considering what it calls a "competency-based approach," which means evaluating AI systems based on their ability to perform specific tasks safely and accurately, rather than applying a one-size-fits-all standard.

The guidance will address several key areas:

• Broad Policy Framework: General principles for how the FDA will evaluate and approve medical devices that use generative AI technology across all healthcare applications.
• Specialized Guidance: Detailed rules for specific types of AI applications that present unique challenges or complexity, such as AI systems used in diagnostic imaging or treatment planning.
• Safety and Effectiveness Standards: Requirements for demonstrating that AI-powered devices work as intended and don't pose unexpected risks to patients.

How Will This Affect Healthcare Innovation?

The promise of formal FDA guidance is significant for the health technology industry. Companies developing AI-powered diagnostic tools, remote monitoring systems, and clinical decision-support software have been operating in a regulatory gray zone, unsure whether their products would face approval delays or unexpected requirements. Clear rules should accelerate development while ensuring patient safety.

For patients and healthcare providers, the new guidance means that AI-powered medical devices will undergo consistent evaluation before reaching the market. This could speed up access to beneficial technologies while reducing the risk of unproven or unsafe AI systems being deployed in clinical settings.

The FDA's commitment to releasing both broad and specialized guidance reflects the reality that generative AI in healthcare isn't a single category. A chatbot designed to answer patient questions about medication side effects requires different oversight than an AI system trained to detect early signs of cancer in medical images. By developing targeted guidance for different applications, the FDA aims to balance innovation with patient protection.

While the agency hasn't announced a specific timeline for releasing the guidance documents, Abramson's statement signals that formal policies are in development and should be forthcoming. For companies, healthcare systems, and patients watching this space, that clarity cannot come soon enough.